Diagnostic Workup for MS and Transverse Myelitis in a 27-Year-Old Female
Obtain brain and complete spinal cord MRI with gadolinium contrast at initial presentation, combined with CSF analysis including oligoclonal bands and cell count, plus serum aquaporin-4 (NMO-IgG) antibodies to distinguish between MS, neuromyelitis optica spectrum disorder (NMOSD), and idiopathic transverse myelitis 1, 2.
Initial Imaging Protocol
The cornerstone of diagnosis is MRI imaging of both brain and entire spinal cord with intravenous gadolinium-based contrast 1. This single initial scan serves multiple critical purposes:
- Excludes compressive myelopathy (surgical emergency that mimics transverse myelitis clinically) 3
- Demonstrates dissemination in time (DIT) when both enhancing and non-enhancing lesions are present simultaneously 1
- Establishes baseline for future comparison 1
- Differentiates MS from NMOSD based on lesion characteristics 2, 4
Brain MRI Technical Requirements
Use 1.5T or 3T scanners with maximum 1×1 mm in-plane resolution 1. The core sequences must include:
- 3D T2-FLAIR (primary sequence for lesion identification)
- T2-weighted sequences for lesion confirmation
- Susceptibility-sensitive imaging to identify central vein sign (CVS) or paramagnetic rim lesions, which are highly specific for MS 1
Spinal Cord MRI Technical Requirements
Image the entire spinal cord (cervical through conus medullaris), not just symptomatic regions 1, 4. Contiguous slices with maximum 3mm thickness on older scanners, or preferably 3D acquisitions with ≤1mm isotropic voxels 1.
Critical Lesion Pattern Recognition
The MRI lesion pattern determines the differential diagnosis and guides subsequent workup 5, 4:
Acute Partial Transverse Myelitis (APTM)
- Short segment (<3 vertebral segments)
- Ovoid or peripherally located lesions
- Strongly suggests MS, especially in young females 2, 4
- Brain MRI showing periventricular white matter lesions consistent with MS predicts conversion to MS 2
Acute Complete Transverse Myelitis (ACTM)
- Longitudinally extensive (≥3 vertebral segments)
- Central cord involvement with complete cross-sectional inflammation
- Suggests NMOSD or idiopathic TM 2, 4
- Requires immediate NMO-IgG testing 2
Additional Patterns to Recognize
- Polio-like (anterior horn involvement): infectious or enteroviral etiology 5, 4
- Granulomatous nodular enhancement: sarcoidosis, tuberculosis 5, 4
- Symmetrical tract-specific: subacute combined degeneration, paraneoplastic 5
Essential Laboratory Testing
CSF Analysis (Mandatory)
Perform lumbar puncture for 2, 3:
- Cell count and differential (elevated in inflammatory conditions)
- Oligoclonal bands (present in 60-90% of MS cases, helps distinguish MS from NMOSD)
- Protein and glucose
- Myelin basic protein (supports demyelination)
Serum Antibody Testing (Critical for Diagnosis)
Level B evidence: NMO-IgG (aquaporin-4 antibodies) testing is essential 2. This test:
- Determines if ACTM is due to NMOSD
- Predicts recurrence risk (positive = high relapse risk)
- Distinguishes NMOSD from MS (lesions >3 segments favor NMOSD) 2
Additional antibody panel based on clinical context 6, 7:
- MOG-IgG antibodies (MOG-associated disease)
- Rheumatoid factor and anti-CCP (RA-associated TM, though rare) 7
- ANA, anti-dsDNA (lupus myelitis)
- Infectious serologies if clinically indicated
Diagnostic Algorithm Based on Findings
If Brain MRI Shows ≥4 Typical MS Locations
MS can be diagnosed immediately without additional evidence if lesions are present in periventricular, juxtacortical, infratentorial, and spinal cord regions 1.
If Brain MRI Shows <4 Typical Locations
Additional evidence required 1:
- DIT demonstration: New T2 lesions on follow-up MRI (can be done without gadolinium) OR simultaneous enhancing and non-enhancing lesions on initial scan
- Highly specific MS features: CVS or paramagnetic rim lesions on susceptibility imaging
- CSF findings: Oligoclonal bands
If Spinal Lesion is Longitudinally Extensive (≥3 Segments)
Priority workup for NMOSD 2, 4:
- NMO-IgG antibodies (aquaporin-4) - Level B recommendation
- MOG-IgG antibodies
- Consider systemic autoimmune workup if seronegative
If MRI is Negative Despite Clinical Myelitis
This occurs in rare cases 7. Proceed with:
- CSF analysis (may show elevated gamma globulins, positive myelin basic protein)
- Electrophysiological studies to confirm central process
- Empiric treatment with high-dose corticosteroids should not be delayed
- Repeat MRI in 2-4 weeks may reveal lesions
- Consider broader autoimmune panel
Follow-Up Imaging Strategy
Repeat brain MRI without gadolinium at 3-6 months to assess for new T2-FLAIR lesions demonstrating DIT 1. The probability of finding isolated new spinal cord lesions without brain lesions is low, so routine repeat spinal imaging is not recommended unless new symptoms develop 1.
Common Pitfalls to Avoid
Do not skip complete spinal cord imaging - imaging only the symptomatic level misses dissemination and alternative diagnoses 1, 4
Do not assume short lesions exclude NMOSD - NMOSD can present with short segment myelitis initially 4
Do not delay treatment waiting for antibody results - initiate corticosteroids based on clinical and MRI findings; antibodies guide long-term management 3, 6
Do not forget to exclude compressive myelopathy first - this is a surgical emergency that presents identically to inflammatory myelitis 3
Do not rely solely on imaging - up to 30% of patients may have MRI-negative myelitis early in disease course 7
Age and Gender Considerations
In a 27-year-old female specifically 2:
- Higher likelihood of MS than other etiologies (female predominance, typical age of onset)
- Lower likelihood of spinal infarction (more common in older patients)
- If APTM pattern: very high probability of MS conversion, warranting close follow-up
Treatment Implications of Workup
The diagnostic distinction has immediate therapeutic consequences: